The US Food and Drug Administration (FDA) approved two CD19 CAR T-cell products in 2017, which have shown clinical efficacy in the treatment of relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) and r/r non-Hodgkin lymphoma (NHL). Here, CD19 is linked to acute lymphoblastic leukemia.